Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 152

1.

Resistance of parvalbumin to gastrointestinal digestion is required for profound and long-lasting prophylactic oral tolerance.

Freidl R, Gstöttner A, Baranyi U, Swoboda I, Stolz F, Focke-Tejkl M, Wekerle T, van Ree R, Valenta R, Linhart B.

Allergy. 2019 Jul 20. doi: 10.1111/all.13994. [Epub ahead of print]

PMID:
31325321
2.

Treg-mediated prolonged survival of skin allografts without immunosuppression.

Pilat N, Wiletel M, Weijler AM, Steiner R, Mahr B, Warren J, Corpuz TM, Wekerle T, Webster KE, Sprent J.

Proc Natl Acad Sci U S A. 2019 Jul 2;116(27):13508-13516. doi: 10.1073/pnas.1903165116. Epub 2019 Jun 13.

PMID:
31196957
3.

Quality, quality, quality.

Wekerle T, Oberbauer R.

Transpl Int. 2019 Jan;32(1):5. doi: 10.1111/tri.13383. No abstract available.

PMID:
30569655
4.

Hybrid resistance to parental bone marrow grafts in nonlethally irradiated mice.

Mahr B, Pilat N, Granofszky N, Wiletel M, Muckenhuber M, Maschke S, Hock K, Wekerle T.

Am J Transplant. 2019 Feb;19(2):591-596. doi: 10.1111/ajt.15146. Epub 2018 Nov 16.

5.

Blocking CD40/CD40L for Chimerism-based Tolerance: Lost in Translation?

Schwarz C, Wekerle T.

Transplantation. 2019 Jan;103(1):10-12. doi: 10.1097/TP.0000000000002418. No abstract available.

PMID:
30113995
6.

CTLA4Ig Improves Murine iTreg Induction via TGFβ and Suppressor Function In Vitro.

Pilat N, Mahr B, Gattringer M, Baranyi U, Wekerle T.

J Immunol Res. 2018 Jul 2;2018:2484825. doi: 10.1155/2018/2484825. eCollection 2018.

7.

Allograft rejection is associated with development of functional IgE specific for donor MHC antigens.

Farkas AM, Baranyi U, Böhmig GA, Unger L, Hopf S, Wahrmann M, Regele H, Mahr B, Schwarz C, Hock K, Pilat N, Kristo I, Mraz J, Lupinek C, Thalhamer J, Bond G, Kuessel L, Wlodek E, Martin J, Clatworthy M, Pettigrew G, Valenta R, Wekerle T.

J Allergy Clin Immunol. 2019 Jan;143(1):335-345.e12. doi: 10.1016/j.jaci.2018.06.034. Epub 2018 Aug 9.

8.

Allograft and patient survival after sequential HSCT and kidney transplantation from the same donor-A multicenter analysis.

Eder M, Schwarz C, Kammer M, Jacobsen N, Stavroula ML, Cowan MJ, Chongkrairatanakul T, Gaston R, Ravanan R, Ishida H, Bachmann A, Alvarez S, Koch M, Garrouste C, Duffner UA, Cullis B, Schaap N, Medinger M, Sørensen SS, Dauber EM, Böhmig G, Regele H, Berlakovich GA, Wekerle T, Oberbauer R.

Am J Transplant. 2019 Feb;19(2):475-487. doi: 10.1111/ajt.14970. Epub 2018 Jul 13.

9.

Belatacept/CTLA4Ig: an update and critical appraisal of preclinical and clinical results.

Schwarz C, Mahr B, Muckenhuber M, Wekerle T.

Expert Rev Clin Immunol. 2018 Jul;14(7):583-592. doi: 10.1080/1744666X.2018.1485489. Epub 2018 Jun 25. Review.

PMID:
29874474
10.

Blockade of adhesion molecule lymphocyte function-associated antigen-1 improves long-term heart allograft survival in mixed chimeras.

Pilat N, Sabler P, Klaus C, Mahr B, Unger L, Hock K, Wiletel M, Schwarz C, Kristo I, Regele H, Wekerle T.

J Heart Lung Transplant. 2018 Sep;37(9):1119-1130. doi: 10.1016/j.healun.2018.03.016. Epub 2018 Mar 30.

PMID:
29699851
11.

Transplantation Tolerance through Hematopoietic Chimerism: Progress and Challenges for Clinical Translation.

Mahr B, Granofszky N, Muckenhuber M, Wekerle T.

Front Immunol. 2017 Dec 22;8:1762. doi: 10.3389/fimmu.2017.01762. eCollection 2017. Review.

12.

Clinical validation of a novel enzyme-linked immunosorbent spot assay-based in vitro diagnostic assay to monitor cytomegalovirus-specific cell-mediated immunity in kidney transplant recipients: a multicenter, longitudinal, prospective, observational study.

Banas B, Steubl D, Renders L, Chittka D, Banas MC, Wekerle T, Koch M, Witzke O, Mühlfeld A, Sommerer C, Habicht A, Hugo C, Hünig T, Lindemann M, Schmidt T, Rascle A, Barabas S, Deml L, Wagner R, Krämer BK, Krüger B.

Transpl Int. 2018 Apr;31(4):436-450. doi: 10.1111/tri.13110. Epub 2018 Jan 16.

13.

Transplant International in a nutshell.

Wekerle T, Oberbauer R.

Transpl Int. 2018 Jan;31(1):5. doi: 10.1111/tri.13107. No abstract available.

14.

No augmentation of indoleamine 2,3-dioxygenase (IDO) activity through belatacept treatment in liver transplant recipients.

Bigenzahn S, Juergens B, Mahr B, Pratschke J, Koenigsrainer A, Becker T, Fuchs D, Brandacher G, Kainz A, Muehlbacher F, Wekerle T.

Clin Exp Immunol. 2018 May;192(2):233-241. doi: 10.1111/cei.13093. Epub 2018 Feb 2.

15.

Combining Adoptive Treg Transfer with Bone Marrow Transplantation for Transplantation Tolerance.

Pilat N, Granofszky N, Wekerle T.

Curr Transplant Rep. 2017;4(4):253-261. doi: 10.1007/s40472-017-0164-7. Epub 2017 Nov 4. Review.

16.

Inflammatory response and oxidative stress during liver resection.

Schwarz C, Fitschek F, Bar-Or D, Klaus DA, Tudor B, Fleischmann E, Roth G, Tamandl D, Wekerle T, Gnant M, Bodingbauer M, Kaczirek K.

PLoS One. 2017 Oct 18;12(10):e0185685. doi: 10.1371/journal.pone.0185685. eCollection 2017.

17.

Recombinant allergen and peptide-based approaches for allergy prevention by oral tolerance.

Campana R, Huang HJ, Freidl R, Linhart B, Vrtala S, Wekerle T, Karaulov A, Valenta R.

Semin Immunol. 2017 Apr;30:67-80. doi: 10.1016/j.smim.2017.08.017. Epub 2017 Sep 20. Review.

PMID:
28939389
18.

Anti-Interleukin-6 Promotes Allogeneic Bone Marrow Engraftment and Prolonged Graft Survival in an Irradiation-Free Murine Transplant Model.

Granofszky N, Farkas AM, Muckenhuber M, Mahr B, Unger L, Maschke S, Pilat N, Holly R, Wiletel M, Regele H, Wekerle T.

Front Immunol. 2017 Jul 19;8:821. doi: 10.3389/fimmu.2017.00821. eCollection 2017.

19.

Immune tolerance in transplantation.

Wekerle T.

Clin Exp Immunol. 2017 Aug;189(2):133-134. doi: 10.1111/cei.12994. No abstract available.

20.

T Cell Subsets Predicting Belatacept-Resistant Rejection: Finding the Root Where the Trouble Starts.

Wekerle T.

Am J Transplant. 2017 Sep;17(9):2235-2237. doi: 10.1111/ajt.14390. Epub 2017 Jul 11. No abstract available.

21.

Strategies for long-term preservation of kidney graft function.

Wekerle T, Segev D, Lechler R, Oberbauer R.

Lancet. 2017 May 27;389(10084):2152-2162. doi: 10.1016/S0140-6736(17)31283-7. Review.

PMID:
28561006
22.

Regulatory T Cells Promote Natural Killer Cell Education in Mixed Chimeras.

Mahr B, Pilat N, Maschke S, Granofszky N, Schwarz C, Unger L, Hock K, Farkas AM, Klaus C, Regele H, Wekerle T.

Am J Transplant. 2017 Dec;17(12):3049-3059. doi: 10.1111/ajt.14342. Epub 2017 Jun 6.

23.

Murine models of transplantation tolerance through mixed chimerism: advances and roadblocks.

Mahr B, Wekerle T.

Clin Exp Immunol. 2017 Aug;189(2):181-189. doi: 10.1111/cei.12976. Epub 2017 May 22. Review.

24.

A B Cell Epitope Peptide Derived from the Major Grass Pollen Allergen Phl p 1 Boosts Allergen-Specific Secondary Antibody Responses without Allergen-Specific T Cell Help.

Narayanan M, Freidl R, Focke-Tejkl M, Baranyi U, Wekerle T, Valenta R, Linhart B.

J Immunol. 2017 Feb 15;198(4):1685-1695. doi: 10.4049/jimmunol.1501741. Epub 2017 Jan 16.

25.

Never stand still.

Wekerle T, Oberbauer R.

Transpl Int. 2017 Jan;30(1):5. doi: 10.1111/tri.12908. No abstract available.

26.

Blocking antibodies induced by immunization with a hypoallergenic parvalbumin mutant reduce allergic symptoms in a mouse model of fish allergy.

Freidl R, Gstoettner A, Baranyi U, Swoboda I, Stolz F, Focke-Tejkl M, Wekerle T, van Ree R, Valenta R, Linhart B.

J Allergy Clin Immunol. 2017 Jun;139(6):1897-1905.e1. doi: 10.1016/j.jaci.2016.10.018. Epub 2016 Nov 19.

27.

Minor Antigen Disparities Impede Induction of Long Lasting Chimerism and Tolerance through Bone Marrow Transplantation with Costimulation Blockade.

Bigenzahn S, Pree I, Klaus C, Pilat N, Mahr B, Schwaiger E, Nierlich P, Wrba F, Wekerle T.

J Immunol Res. 2016;2016:8635721. Epub 2016 Oct 31.

28.

Effect of Ex Vivo-Expanded Recipient Regulatory T Cells on Hematopoietic Chimerism and Kidney Allograft Tolerance Across MHC Barriers in Cynomolgus Macaques.

Duran-Struuck R, Sondermeijer HP, Bühler L, Alonso-Guallart P, Zitsman J, Kato Y, Wu A, McMurchy AN, Woodland D, Griesemer A, Martinez M, Boskovic S, Kawai T, Cosimi AB, Yang YG, Hu Z, Wuu CS, Slate A, Mapara M, Baker S, Tokarz R, D'Agati V, Hammer S, Pereira M, Lipkin WI, Wekerle T, Levings M, Sykes M.

Transplantation. 2017 Feb;101(2):274-283. doi: 10.1097/TP.0000000000001559. Erratum in: Transplantation. 2018 May;102(5):e252. Yang, Yong-Guang [added]; Hu, Zheng [added].

29.

Long-Term Outcomes in Belatacept- Versus Cyclosporine-Treated Recipients of Extended Criteria Donor Kidneys: Final Results From BENEFIT-EXT, a Phase III Randomized Study.

Durrbach A, Pestana JM, Florman S, Del Carmen Rial M, Rostaing L, Kuypers D, Matas A, Wekerle T, Polinsky M, Meier-Kriesche HU, Munier S, Grinyó JM.

Am J Transplant. 2016 Nov;16(11):3192-3201. doi: 10.1111/ajt.13830. Epub 2016 Jun 9.

30.

Oncolytic influenza A virus expressing interleukin-15 decreases tumor growth in vivo.

Hock K, Laengle J, Kuznetsova I, Egorov A, Hegedus B, Dome B, Wekerle T, Sachet M, Bergmann M.

Surgery. 2017 Mar;161(3):735-746. doi: 10.1016/j.surg.2016.08.045. Epub 2016 Oct 21.

PMID:
27776794
31.

Incomplete clonal deletion as prerequisite for tissue-specific minor antigen tolerization.

Pilat N, Mahr B, Unger L, Hock K, Schwarz C, Farkas AM, Baranyi U, Wrba F, Wekerle T.

JCI Insight. 2016 May 19;1(7):e85911. doi: 10.1172/jci.insight.85911.

32.

Introducing the Wiley Transplant Peer Review Network.

Kirk AD, Malchesky PS, Shapiro R, Webber SA, Hirsch HH, Marty FM, Oberbauer R, Wekerle T, Bühler LH, Labbate A, Perry K, Wielgus J.

Am J Transplant. 2016 Sep;16(9):2505-7. doi: 10.1111/ajt.13965. Epub 2016 Aug 16. No abstract available.

33.

Introducing The Wiley Transplant Peer Review Network.

Kirk AD, Malchesky PS, Shapiro R, Webber SA, Hirsch HH, Marty FM, Oberbauer R, Wekerle T, Bühler LH, Labbate A, Perry K, Wielgus J.

Artif Organs. 2016 Jul;40(7):635-7. doi: 10.1111/aor.12772. No abstract available.

PMID:
27378614
34.

Cell Therapy for Prophylactic Tolerance in Immunoglobulin E-mediated Allergy.

Baranyi U, Farkas AM, Hock K, Mahr B, Linhart B, Gattringer M, Focke-Tejkl M, Petersen A, Wrba F, Rülicke T, Valenta R, Wekerle T.

EBioMedicine. 2016 May;7:230-9. doi: 10.1016/j.ebiom.2016.03.028. Epub 2016 Mar 20.

35.

The Immunosuppressive Effect of CTLA4 Immunoglobulin Is Dependent on Regulatory T Cells at Low But Not High Doses.

Schwarz C, Unger L, Mahr B, Aumayr K, Regele H, Farkas AM, Hock K, Pilat N, Wekerle T.

Am J Transplant. 2016 Dec;16(12):3404-3415. doi: 10.1111/ajt.13872. Epub 2016 Jul 5.

36.

Kidney Transplantation With Corticosteroids Alone After Haploidentical HSCT From The Same Donor.

Schwarz C, Lawitschka A, Böhmig GA, Dauber EM, Greinix H, Kozakowski N, Mühlbacher F, Berlakovich GA, Wekerle T.

Transplantation. 2016 Oct;100(10):2219-21. doi: 10.1097/TP.0000000000001213.

PMID:
27136263
37.

Distinctive Expression of Bcl-2 Factors in Regulatory T Cells Determines a Pharmacological Target to Induce Immunological Tolerance.

Gabriel SS, Bon N, Chen J, Wekerle T, Bushell A, Fehr T, Cippà PE.

Front Immunol. 2016 Mar 1;7:73. doi: 10.3389/fimmu.2016.00073. eCollection 2016.

38.

The DESCARTES-Nantes survey of kidney transplant recipients displaying clinical operational tolerance identifies 35 new tolerant patients and 34 almost tolerant patients.

Massart A, Pallier A, Pascual J, Viklicky O, Budde K, Spasovski G, Klinger M, Sever MS, Sørensen SS, Hadaya K, Oberbauer R, Dudley C, De Fijter JW, Yussim A, Hazzan M, Wekerle T, Berglund D, De Biase C, Pérez-Sáez MJ, Mühlfeld A, Orlando G, Clemente K, Lai Q, Pisani F, Kandus A, Baas M, Bemelman F, Ponikvar JB, Mazouz H, Stratta P, Subra JF, Villemain F, Hoitsma A, Braun L, Cantarell MC, Colak H, Courtney A, Frasca GM, Howse M, Naesens M, Reischig T, Serón D, Seyahi N, Tugmen C, Alonso Hernandez A, Beňa L, Biancone L, Cuna V, Díaz-Corte C, Dufay A, Gaasbeek A, Garnier A, Gatault P, Gentil Govantes MA, Glowacki F, Gross O, Hurault de Ligny B, Huynh-Do U, Janbon B, Jiménez Del Cerro LA, Keller F, La Manna G, Lauzurica R, Le Monies De Sagazan H, Thaiss F, Legendre C, Martin S, Moal MC, Noël C, Pillebout E, Piredda GB, Puga AR, Sulowicz W, Tuglular S, Prokopova M, Chesneau M, Le Moine A, Guérif P, Soulillou JP, Abramowicz M, Giral M, Racapé J, Maggiore U, Brouard S, Abramowicz D.

Nephrol Dial Transplant. 2016 Jun;31(6):1002-13. doi: 10.1093/ndt/gfv437. Epub 2016 Jan 12.

PMID:
26763669
39.

IL-2/α-IL-2 Complex Treatment Cannot Be Substituted for the Adoptive Transfer of Regulatory T cells to Promote Bone Marrow Engraftment.

Mahr B, Unger L, Hock K, Pilat N, Baranyi U, Schwarz C, Maschke S, Farkas AM, Wekerle T.

PLoS One. 2016 Jan 5;11(1):e0146245. doi: 10.1371/journal.pone.0146245. eCollection 2016.

40.

Anti-OX40L alone or in combination with anti-CD40L and CTLA4Ig does not inhibit the humoral and cellular response to a major grass pollen allergen.

Gattringer M, Baranyi U, Pilat N, Hock K, Klaus C, Ramsey HE, Wrba F, Valenta R, Wekerle T.

Clin Exp Allergy. 2016 Feb;46(2):354-64. doi: 10.1111/cea.12661.

41.

Transection Speed and Impact on Perioperative Inflammatory Response - A Randomized Controlled Trial Comparing Stapler Hepatectomy and CUSA Resection.

Schwarz C, Klaus DA, Tudor B, Fleischmann E, Wekerle T, Roth G, Bodingbauer M, Kaczirek K.

PLoS One. 2015 Oct 9;10(10):e0140314. doi: 10.1371/journal.pone.0140314. eCollection 2015.

42.

Strategies to overcome the ABO barrier in kidney transplantation.

Böhmig GA, Farkas AM, Eskandary F, Wekerle T.

Nat Rev Nephrol. 2015 Dec;11(12):732-47. doi: 10.1038/nrneph.2015.144. Epub 2015 Sep 1. Review.

PMID:
26324199
43.

Polyclonal Recipient nTregs Are Superior to Donor or Third-Party Tregs in the Induction of Transplantation Tolerance.

Pilat N, Klaus C, Hock K, Baranyi U, Unger L, Mahr B, Farkas AM, Wrba F, Wekerle T.

J Immunol Res. 2015;2015:562935. doi: 10.1155/2015/562935. Epub 2015 Jul 27.

44.

Deletional and regulatory mechanisms coalesce to drive transplantation tolerance through mixed chimerism.

Hock K, Mahr B, Schwarz C, Wekerle T.

Eur J Immunol. 2015 Sep;45(9):2470-9. doi: 10.1002/eji.201545494. Review.

45.

Rapamycin and CTLA4Ig synergize to induce stable mixed chimerism without the need for CD40 blockade.

Pilat N, Klaus C, Schwarz C, Hock K, Oberhuber R, Schwaiger E, Gattringer M, Ramsey H, Baranyi U, Zelger B, Brandacher G, Wrba F, Wekerle T.

Am J Transplant. 2015 Jun;15(6):1568-79. doi: 10.1111/ajt.13154. Epub 2015 Mar 17.

46.

Long-term outcome of belatacept therapy in de novo kidney transplant recipients - a case-match analysis.

Schwarz C, Mayerhoffer S, Berlakovich GA, Steininger R, Soliman T, Watschinger B, Böhmig GA, Eskandary F, König F, Mühlbacher F, Wekerle T.

Transpl Int. 2015 Jul;28(7):820-7. doi: 10.1111/tri.12544. Epub 2015 Mar 6.

47.

Belatacept treatment for two yr after liver transplantation is not associated with operational tolerance.

Schwarz C, Rasoul-Rockenschaub S, Soliman T, Berlakovich GA, Steininger R, Mühlbacher F, Wekerle T.

Clin Transplant. 2015 Jan;29(1):85-9. doi: 10.1111/ctr.12483. Epub 2014 Dec 10.

PMID:
25377272
48.

CTLA4-Ig preserves thymus-derived T regulatory cells.

Ahmadi SM, Hölzl MA, Mayer E, Wekerle T, Heitger A.

Transplantation. 2014 Dec 15;98(11):1158-64. doi: 10.1097/TP.0000000000000421.

PMID:
25269023
49.

Donor CD4 T cells trigger costimulation blockade-resistant donor bone marrow rejection through bystander activation requiring IL-6.

Hock K, Pilat N, Baranyi U, Mahr B, Gattringer M, Klaus C, Wekerle T.

Am J Transplant. 2014 Sep;14(9):2011-22. doi: 10.1111/ajt.12823. Epub 2014 Aug 6.

50.

Belatacept-based immunosuppression in de novo liver transplant recipients: 1-year experience from a phase II randomized study.

Klintmalm GB, Feng S, Lake JR, Vargas HE, Wekerle T, Agnes S, Brown KA, Nashan B, Rostaing L, Meadows-Shropshire S, Agarwal M, Harler MB, Garcia-Valdecasas JC.

Am J Transplant. 2014 Aug;14(8):1817-27.

Supplemental Content

Loading ...
Support Center